Chemours/$CC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Chemours

The Chemours Co is a provider of chemicals. It delivers customized solutions with a wide range of industrial and specialty chemicals products for various markets including coatings, plastics, refrigeration, air conditioning, etc. The company's operating segments include Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. It generates maximum revenue from the Titanium Technologies segment. The Titanium Technologies segment is a producer of TiO2 pigment, a premium white pigment used to deliver whiteness, brightness, opacity, durability, efficiency, and protection across a variety of applications. Geographically, the company derives a majority of its revenue from North America.

Ticker

$CC
Sector

Primary listing

NYSE

Employees

6,000

Chemours Metrics

BasicAdvanced
$2.1B
-
-$2.75
1.63
$0.68
2.54%

What the Analysts think about Chemours

Analyst ratings (Buy, Hold, Sell) for Chemours stock.

Bulls say / Bears say

Chemours and DuPont agreed to pay a combined $671 million to settle C-8 lawsuits, with Chemours’s share $300 million below Wall Street estimates—an outcome that drove a 13% jump in Chemours shares on resolution of key legacy liabilities (Reuters)
Appointment of long‐time company insider Jonathan Lock as CFO brings financial leadership with proven experience in executing strategic divestitures, suggesting potential for improved capital allocation and operational focus (Reuters)
The August agreement to settle New Jersey PFAS claims for $875 million—with Chemours’s 50% share having a pre-tax present value of about $500 million—provides clarity and caps legacy PFAS liabilities, reducing overhang on future earnings (Reuters)
Dutch court ruling holds Chemours liable for PFAS-related environmental damage in the Netherlands, exposing it to potential further litigation and remediation costs across Europe (Reuters)
Under the New Jersey settlement, Chemours must pay 50% of the $875 million over 25 years—representing a present value of approximately $500 million before taxes—adding substantial long-term cash obligations and pressure on liquidity (Reuters)
The abrupt replacement of longtime CFO Sameer Ralhan with insider Jonathan Lock, announced without public explanation, raises concerns over potential governance issues and executive distraction amid legal challenges (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.

Chemours Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Chemours Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CC

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs